Pfizer, Sarepta team with fellow DMD gene therapy makers to get to the bottom of adverse events Google Health hires FDA's former digital health chief to lead global strategy Pfizer, Merck and AstraZeneca led Big Pharma's growth in Q1 but they couldn't match mRNA hotshots Sernova taps Evotec’s insulin-producing cells to fill its pouch implant for diabetes AstraZeneca bags pan-variant COVID-19 antibodies from stealthy biotech in $157M deal RAND: Private plans paid hospitals 224% more than Medicare rates Novartis faces Greek bribery lawsuit as government prepares to seek compensation Researchers develop battery-free, smart contact lens that delivers glaucoma drugs on demand FDA has change of heart, plans to convene advisory meeting for Cytokinetics' cardiac med Labcorp's combo COVID, flu, RSV test nabs first green light for direct-to-consumer sales by FDA Gardasil vaccine maker Merck appeals to parents of 9-year-olds in latest HPV awareness ad 24 states support federal government in 340B drugmaker lawsuit Ampio's years of troubles come to a head with internal investigation, trio of COVID trial failures FDA smiles on 2nd cavity-spotting AI in a month with clearance for Overjet's tech Featured Story | By Annalee Armstrong The four companies working on gene therapies for Duchenne muscular dystrophy have had another thing in common besides the modality and disease they’re working on: serious adverse events. Pfizer, Sarepta, Genethon and Solid Biosciences teamed up for a pooled safety analysis that was presented this week at the American Society of Gene and Cell Therapy meeting. read more |
| |
|---|
|
Top Stories By Heather Landi As Google pushes further into healthcare, the tech company has gotten good at poaching talent from health systems and regulatory agencies. Google has tapped Bakul Patel, the former head of digital health at the FDA, to develop and lead its unified digital health and regulatory strategy. read more By Kevin Dunleavy Big Pharma posted major growth in the first quarter of 2022, providing more evidence of the industry’s rebound from the pandemic. Most of the growth leaders sell COVID-19 products. A quarter-over-quarter comparison however told a different tale as seasonal effects prevented most companies from exceeding their fourth-quarter revenues. read more By Andrea Park Sernova's Cell Pouch system has already produced promising results in clinical trials using human donor cells, and now, it has brought German biotech Evotec on board to help fill them with insulin-producing cells. read more By Nick Paul Taylor AstraZeneca is keeping its foot on the gas on COVID-19 R&D, striking a deal to license RQ Biotechnology’s early-stage monoclonal antibodies against SARS-CoV-2 in a deal worth up to $157 million plus royalties. read more By Robert King A new study from RAND found that employer and private health plans paid hospitals 224% more in 2020 compared to Medicare. read more By Angus Liu After years of investigating and political finger-pointing, the Greek government is still pressing bribery allegations against Novartis and is now promising legal action. read more By Conor Hale Researchers in China have put forward early studies of a smart contact lens for treating glaucoma. It aims to sense rising fluid pressures within the eye and automatically deliver medication as needed. read more By Max Bayer The FDA will convene an advisory committee to discuss Cytokinetics inconsistent heart failure med after all, more than three months after the agency first indicated it would not. read more By Andrea Park The Labcorp test requires only a single nasal swab to detect COVID-19, RSV and influenza A and B. The sample is self-collected in a patient’s own home, then sent off to the diagnostic lab giant for processing. read more By Natalie Missakian It’s unlikely parents of 9-year-olds are thinking much about their child contracting HPV. But a new unbranded TV ad from Merck reminds them that this is precisely the age when they can start immunizing their children against the human papilloma virus to prevent future cancers. read more By Robert King A collection of 24 states announced support for the federal government who are in several lawsuits with drugmakers over 340B restrictions. read more By Annalee Armstrong An osteoarthritis trial ravaged by COVID, an FDA rejection, three failed clinical trials in COVID and now this: Ampio’s board is conducting an internal investigation. read more By Andrea Park Not content to simply grin and bear it as another dental artificial intelligence developer, VideaHealth, snagged FDA clearance for cavity-spotting AI just a few weeks ago, Overjet has quickly followed suit. read more |
